Chun Dang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chun Dang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ying Xiong
Department of Periodical Press/Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
3 shared publications - Li Feng
Department of General Surgery and Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Yaoheng Lu
Department of General Surgery, Chengdu Integrated Traditional Chinese Medicine and Western Medicine Hospital, Chengdu, China
2 shared publications - Yaoheng Lu
Department of General Surgery, Chengdu Integrated Traditional Chinese Medicine and Western Medicine Hospital, China
2 shared publications Qian Li
Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
1 shared publication- Qian Li
Department of Neurology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China
1 shared publication
Latest Publications
- 26 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (3) , 293
Service delivery, behavioural, and self-management interventions for adults with epilepsy: summary of a Cochrane systematic review
- 26 February 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (3) , 293
Service delivery, behavioural, and self-management interventions for adults with epilepsy: summary of a Cochrane systematic review
- 18 August 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6427-6430
Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review
Progressive multiple sclerosis (PMS) remains a therapeutic challenge, with limited effective treatments and a high degree of uncertainty surrounding long-term efficacy and safety. In this context, the recently published Cochrane network meta-analysis by Ridley et al. (2024) represents a significant effort to synthesise available evidence on immunomodulatory and immunosuppressive therapies in PMS. This article provides a structured summary and critical commentary on the findings of the Cochrane review. It highlights key clinical insights, evidence gaps, and methodological limitations that have implications for practice and future research. Based on data from 23 randomised controlled trials involving over 10,000 participants, the Cochrane review reported modest relapse-reducing effects for rituximab and interferon beta-1b. However, no interventions demonstrated consistent or high-certainty evidence for delaying disability progression. Interferon beta-1a was associated with a higher rate of treatment discontinuation due to adverse events. Notably, the majority of studies had short follow-up durations and did not assess health-related quality of life. Our commentary underscores the limited clinical impact of current therapies in PMS and the persistent uncertainty in the evidence base. We advocate for more robust, independent trials incorporating longer follow-up, head-to-head comparisons, and standardised, patientcentred outcome reporting. We also call attention to the need for better integration of real-world data to improve the applicability of trial findings. This Cochrane review provides timely and methodologically sound evidence on pharmacological management in PMS. However, the overall modest benefits observed reinforce the urgent need for high-quality, patient-focused research to guide future therapeutic development and clinical decision-making.
- 18 August 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (12) , 6427-6430
Therapeutic evaluation of immunomodulators and immunosuppressants in progressive multiple sclerosis: summary of a Cochrane systematic review
Progressive multiple sclerosis (PMS) remains a therapeutic challenge, with limited effective treatments and a high degree of uncertainty surrounding long-term efficacy and safety. In this context, the recently published Cochrane network meta-analysis by Ridley et al. (2024) represents a significant effort to synthesise available evidence on immunomodulatory and immunosuppressive therapies in PMS. This article provides a structured summary and critical commentary on the findings of the Cochrane review. It highlights key clinical insights, evidence gaps, and methodological limitations that have implications for practice and future research. Based on data from 23 randomised controlled trials involving over 10,000 participants, the Cochrane review reported modest relapse-reducing effects for rituximab and interferon beta-1b. However, no interventions demonstrated consistent or high-certainty evidence for delaying disability progression. Interferon beta-1a was associated with a higher rate of treatment discontinuation due to adverse events. Notably, the majority of studies had short follow-up durations and did not assess health-related quality of life. Our commentary underscores the limited clinical impact of current therapies in PMS and the persistent uncertainty in the evidence base. We advocate for more robust, independent trials incorporating longer follow-up, head-to-head comparisons, and standardised, patientcentred outcome reporting. We also call attention to the need for better integration of real-world data to improve the applicability of trial findings. This Cochrane review provides timely and methodologically sound evidence on pharmacological management in PMS. However, the overall modest benefits observed reinforce the urgent need for high-quality, patient-focused research to guide future therapeutic development and clinical decision-making.
- Open Access
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43789
Chinese herbal medicine for insomnia: A systematic review and network meta-analysis
Objective: Insomnia represents a significant public health issue, with a notable impact on the global burden of disease. Traditional pharmacological interventions, while effective, often entail limitations and adverse effects, necessitating the exploration of alternative therapeutic modalities. Chinese herbal medicines, with their extensive historical use and presumed multifaceted pharmacological actions, emerge as potential candidates for insomnia management. Methods: In strict adherence to the PRISMA-NMA guidelines, we systematically reviewed randomized controlled trials (RCTs) that investigated the therapeutic effects of Chinese herbal medicines on insomnia. The primary outcomes assessed were improvements in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), clinical effectiveness rates, and the incidence of adverse reactions. Comprehensive searches were conducted across several databases including MEDLINE, Cochrane Library, EMBASE, Wanfang Data, CNKI, and gray literature. Both direct and indirect evidence was synthesized using Bayesian network meta-analysis techniques to ascertain the relative performance of various herbal interventions. Results: The analysis included 186 RCTs involving 13 different herbal interventions. Overall, the included studies exhibited a low-to-moderate risk-of-bias. Key findings from our study suggest that for PSQI scores, the top 5 treatments were guipi decoction, shenqi schisandra tablet, chaihu longgu muli decoction (CLMD), suanzaoren, and wuling capsule. Notably, the highest rankings for effective rate were achieved by longdan xiegan decoction, CLMD, guipi decoction, Huanglian Wendan decoction, and chaihu shugan powder. In terms of safety, jieyu pill, trazodone, and CLMD were the top 3, indicating superior safety profiles among all treatments. Crucially, both the PSQI scores and the effective rate, alongside the safety profile of most Chinese herbal medicines, were generally superior to conventional pharmaceutical treatments. Conclusion: The study provides robust evidence that certain herbal medicines may offer effective and safe alternatives for managing insomnia, potentially reducing the reliance on conventional pharmacological interventions.
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43789
Open AccessChinese herbal medicine for insomnia: A systematic review and network meta-analysis
Objective: Insomnia represents a significant public health issue, with a notable impact on the global burden of disease. Traditional pharmacological interventions, while effective, often entail limitations and adverse effects, necessitating the exploration of alternative therapeutic modalities. Chinese herbal medicines, with their extensive historical use and presumed multifaceted pharmacological actions, emerge as potential candidates for insomnia management. Methods: In strict adherence to the PRISMA-NMA guidelines, we systematically reviewed randomized controlled trials (RCTs) that investigated the therapeutic effects of Chinese herbal medicines on insomnia. The primary outcomes assessed were improvements in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), clinical effectiveness rates, and the incidence of adverse reactions. Comprehensive searches were conducted across several databases including MEDLINE, Cochrane Library, EMBASE, Wanfang Data, CNKI, and gray literature. Both direct and indirect evidence was synthesized using Bayesian network meta-analysis techniques to ascertain the relative performance of various herbal interventions. Results: The analysis included 186 RCTs involving 13 different herbal interventions. Overall, the included studies exhibited a low-to-moderate risk-of-bias. Key findings from our study suggest that for PSQI scores, the top 5 treatments were guipi decoction, shenqi schisandra tablet, chaihu longgu muli decoction (CLMD), suanzaoren, and wuling capsule. Notably, the highest rankings for effective rate were achieved by longdan xiegan decoction, CLMD, guipi decoction, Huanglian Wendan decoction, and chaihu shugan powder. In terms of safety, jieyu pill, trazodone, and CLMD were the top 3, indicating superior safety profiles among all treatments. Crucially, both the PSQI scores and the effective rate, alongside the safety profile of most Chinese herbal medicines, were generally superior to conventional pharmaceutical treatments. Conclusion: The study provides robust evidence that certain herbal medicines may offer effective and safe alternatives for managing insomnia, potentially reducing the reliance on conventional pharmacological interventions.
- 5 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (9) , 4229-4231
Effectiveness of physical rehabilitation approaches in improving function and mobility after stroke: comprehensive insights from a Cochrane systematic review
- 5 June 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (9) , 4229-4231
Effectiveness of physical rehabilitation approaches in improving function and mobility after stroke: comprehensive insights from a Cochrane systematic review
- Open Access
- 2 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0311231
Synergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: A Bayesian network meta-analysis
Neuroprotective drugs as adjunctive therapy for adults with acute ischemic stroke (AIS) remains contentious. This study summarizes the latest evidence regarding the benefits of neuroprotective agents combined with intravenous recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis. This study conducted a structured search of PubMed, the Cochrane Library, EMBASE, Wanfang Data, and CNKI databases from their inception to March 2024. Grey literature was also searched. The outcomes included efficacy (National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score) and safety (rate of adverse reactions). A total of 70 randomized controlled trials were selected for this network meta-analysis (NMA), encompassing 4,140 patients with AIS treated using different neuroprotective agents plus RT-PA, while 4,012 patients with AIS were in control groups. The top three treatments for NIHSS scores at the 2-week follow-up were Edaravone Dexborneo with 0.9 mg/kg rt-PA, Edaravone with 0.9 mg/kg rt-PA, and HUK with 0.9 mg/kg rt-PA. HUK with 0.9 mg/kg rt-PA, Dl-3n-butylphthalide with 0.9 mg/kg rt-PA, and Edaravone Dexborneo with 0.9 mg/kg rt-PA were ranked the top three for BI scores at the 2-week follow-up. The top three treatments with the lowest adverse effect rates were 0.6 mg/kg rt-PA, HUK with 0.9 mg/kg rt-PA, and Edaravone Dexborneo with 0.9 mg/kg rt-PA due to their excellent safety profiles. Compared to rt-PA alone, the combination treatments of Edaravone+rt-PA, Edaravone Dexborneol+rt-PA, HUK+rt-PA, Dl-3n-butylphthalide+rt-PA, and Ganglioside GM1+rt-PA have shown superior efficacy. This NMA suggest that combination therapies of neuroprotective agents and rt-PA can offer better outcomes for patients with AIS. The results support the potential integration of these combination therapies into standard AIS treatment, aiming for improved patient outcomes and personalized therapeutic approaches.
- 2 December 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (12) , e0311231
Open AccessSynergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: A Bayesian network meta-analysis
Neuroprotective drugs as adjunctive therapy for adults with acute ischemic stroke (AIS) remains contentious. This study summarizes the latest evidence regarding the benefits of neuroprotective agents combined with intravenous recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis. This study conducted a structured search of PubMed, the Cochrane Library, EMBASE, Wanfang Data, and CNKI databases from their inception to March 2024. Grey literature was also searched. The outcomes included efficacy (National Institutes of Health Stroke Scale (NIHSS) score and Barthel Index (BI) score) and safety (rate of adverse reactions). A total of 70 randomized controlled trials were selected for this network meta-analysis (NMA), encompassing 4,140 patients with AIS treated using different neuroprotective agents plus RT-PA, while 4,012 patients with AIS were in control groups. The top three treatments for NIHSS scores at the 2-week follow-up were Edaravone Dexborneo with 0.9 mg/kg rt-PA, Edaravone with 0.9 mg/kg rt-PA, and HUK with 0.9 mg/kg rt-PA. HUK with 0.9 mg/kg rt-PA, Dl-3n-butylphthalide with 0.9 mg/kg rt-PA, and Edaravone Dexborneo with 0.9 mg/kg rt-PA were ranked the top three for BI scores at the 2-week follow-up. The top three treatments with the lowest adverse effect rates were 0.6 mg/kg rt-PA, HUK with 0.9 mg/kg rt-PA, and Edaravone Dexborneo with 0.9 mg/kg rt-PA due to their excellent safety profiles. Compared to rt-PA alone, the combination treatments of Edaravone+rt-PA, Edaravone Dexborneol+rt-PA, HUK+rt-PA, Dl-3n-butylphthalide+rt-PA, and Ganglioside GM1+rt-PA have shown superior efficacy. This NMA suggest that combination therapies of neuroprotective agents and rt-PA can offer better outcomes for patients with AIS. The results support the potential integration of these combination therapies into standard AIS treatment, aiming for improved patient outcomes and personalized therapeutic approaches.
- Open Access
- 2 March 2023
- Published by Oxford University Press (OUP) in Psychoradiology
- Vol. 3, kkad009
Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
Alzheimer's disease (AD) is the most common cause of dementia. Neuropathological changes in AD patients occur up to 10–20 years before the emergence of clinical symptoms. Specific diagnosis and appropriate intervention strategies are crucial during the phase of mild cognitive impairment (MCI) and AD. The detection of biomarkers has emerged as a promising tool for tracking the efficacy of potential therapies, making an early disease diagnosis, and prejudging treatment prognosis. Specifically, multiple neuroimaging modalities, including magnetic resonance imaging (MRI), positron emission tomography, optical imaging, and single photon emission-computed tomography, have provided a few potential biomarkers for clinical application. The MRI modalities described in this review include structural MRI, functional MRI, diffusion tensor imaging, magnetic resonance spectroscopy, and arterial spin labelling. These techniques allow the detection of presymptomatic diagnostic biomarkers in the brains of cognitively normal elderly people and might also be used to monitor AD disease progression after the onset of clinical symptoms. This review highlights potential biomarkers, merits, and demerits of different neuroimaging modalities and their clinical value in MCI and AD patients. Further studies are necessary to explore more biomarkers and overcome the limitations of multiple neuroimaging modalities for inclusion in diagnostic criteria for AD.
- 2 March 2023
- Published by Oxford University Press (OUP) in Psychoradiology
- Vol. 3, kkad009
Open AccessNeuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers
Alzheimer's disease (AD) is the most common cause of dementia. Neuropathological changes in AD patients occur up to 10–20 years before the emergence of clinical symptoms. Specific diagnosis and appropriate intervention strategies are crucial during the phase of mild cognitive impairment (MCI) and AD. The detection of biomarkers has emerged as a promising tool for tracking the efficacy of potential therapies, making an early disease diagnosis, and prejudging treatment prognosis. Specifically, multiple neuroimaging modalities, including magnetic resonance imaging (MRI), positron emission tomography, optical imaging, and single photon emission-computed tomography, have provided a few potential biomarkers for clinical application. The MRI modalities described in this review include structural MRI, functional MRI, diffusion tensor imaging, magnetic resonance spectroscopy, and arterial spin labelling. These techniques allow the detection of presymptomatic diagnostic biomarkers in the brains of cognitively normal elderly people and might also be used to monitor AD disease progression after the onset of clinical symptoms. This review highlights potential biomarkers, merits, and demerits of different neuroimaging modalities and their clinical value in MCI and AD patients. Further studies are necessary to explore more biomarkers and overcome the limitations of multiple neuroimaging modalities for inclusion in diagnostic criteria for AD.